FDA 483 - Glenmark Pharmaceuticals Inc USA - June 17, 2025

Glenmark Pharmaceuticals Inc USA, located in Monroe, NC, underwent an FDA inspection from June 9 to June 17, 2025. The inspection revealed several critical deficiencies in their sterile drug manufacturing processes. Key observations included inadequate procedures to prevent microbiological contamination, particularly in the smoke study evaluation of their prefilled syringe line. The study failed to document airflow patterns effectively due to excessive smoke and poor camera angles, leading to inconclusive contamination sources.

Personnel monitoring was also found deficient, with improper sampling techniques and deviations from established procedures for aseptic techniques. The firm failed to simulate finished product conditions accurately during aseptic process simulations, which is crucial for ensuring product integrity. Additionally, the rationale for not autoclaving gloves between batches and reducing glove integrity testing frequency was unsupported by scientific evidence.

Environmental monitoring was inadequate, with insufficient sampling of critical surfaces, a repeat issue from a previous inspection in 2022. The FDA requires Glenmark Pharmaceuticals to address these violations by establishing robust procedures, enhancing personnel training, and ensuring compliance with aseptic processing standards. Immediate corrective actions and a comprehensive response plan are necessary to align with regulatory expectations and ensure product safety.